NASDAQ:VVOS Vivos Therapeutics Q1 2026 Earnings Results & Report $0.14 0.00 (-1.84%) As of 02:26 PM Eastern This is a fair market value price provided by Massive. Learn more. Vivos Therapeutics missed analyst earnings expectations but beat on revenue in its Q1 2026 results, released May 20, 2026. The company reported EPS of -$0.52 versus the -$0.45 consensus estimate, while revenue of $5.14 million topped the $4.35 million estimate by $0.79 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 20, 2026TimeAfter Market ClosesConference Call4:00 PM ET Vivos Therapeutics EPS ResultsActual EPS-$0.52Consensus EPS -$0.45Beat/MissMissed by -$0.07One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersVivos Therapeutics Revenue ResultsActual Revenue$5.14 millionExpected Revenue$4.35 millionBeat/MissBeat by +$792.00 thousandYoY Revenue GrowthN/AUpcoming EarningsVivos Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vivos Therapeutics Q1 2026 Earnings FAQ Did Vivos Therapeutics beat earnings estimates for Q1 2026? Vivos Therapeutics (NASDAQ:VVOS) reported earnings of -$0.52 per share for Q1 2026, missing the consensus estimate of -$0.45. The report was announced on Wednesday, May 20, 2026. What was Vivos Therapeutics' revenue for Q1 2026? Vivos Therapeutics reported revenue of $5.14 million for Q1 2026, against a consensus estimate of $4.35 million. When is Vivos Therapeutics' next earnings date? Vivos Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Vivos Therapeutics on the company's earnings history page. Vivos Therapeutics Earnings HeadlinesVivos Therapeutics targets $3.6 million in annual cost reductions as revenue growth initiatives accelerateSeptember 29, 2026 | msn.comVivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth InitiativesSeptember 29, 2026 | globenewswire.comA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.October 14 at 1:00 AM | Investors Alley (Ad)Vivos Therapeutics Announces Material Debt ReductionSeptember 8, 2026 | globenewswire.comVivos Therapeutics Advances South Florida Sleep Center With South Palm Cardiovascular PartnershipAugust 28, 2026 | rttnews.comVivos Therapeutics Announces Definitive Agreements With South Palm Cardiovascular Associates to Launch South Florida Sleep & Airway Medicine CenterAugust 28, 2026 | quiverquant.comQSee More Vivos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vivos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivos Therapeutics and other key companies, straight to your email. Email Address About Vivos TherapeuticsVivos Therapeutics (NASDAQ:VVOS) is a medical technology company focused on developing and commercializing non-surgical treatments for sleep-related breathing disorders and related craniofacial conditions. The company’s primary focus is obstructive sleep apnea, a disorder in which the upper airway repeatedly narrows or becomes blocked during sleep. The company markets the Vivos System, a series of customized oral appliances designed to help reposition and support the upper airway. Its offerings include the Vivos Complete Airway Repositioning Appliance (CARE) and other dental devices intended to improve airway function during sleep. Vivos provides products and related clinical support through dentists and other trained healthcare professionals, offering an alternative or complement to traditional treatments such as continuous positive airway pressure therapy. Founded in 2016, Vivos Therapeutics is headquartered in Denver, Colorado, and serves patients primarily through a network of trained dental providers in the United States, with international availability developing through its distribution and provider network. Kirk Huntsman has served as the company’s chief executive officer and has been associated with its leadership since its early development. The company’s common stock trades on the Nasdaq under the symbol VVOS.View Vivos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
